[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"oesophageal-carcinoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:oesophageal-carcinoma":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,41],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100646326","phase-2-a-dose-optimizationexpansion-study-of-sar445877-in-adult-chinese-participants-with-advanced-gastric-or-gastroesophageal-junction-cancer-100646326",false,"NCT07692204","A Dose Optimization\u002FExpansion Study of SAR445877 in Adult Chinese Participants With Advanced Gastric or Gastroesophageal Junction Cancer","A Phase 2, Open-label, Dose Optimization\u002FExpansion Study of SAR445877 Administered as Monotherapy or in Combination With Other Anticancer Therapies in Adults With Advanced Gastric or Gastroesophageal Junction Cancer","Inclusion Criteria:\n\nAge\n\n\\- Participant must be at least 18 years of age inclusive (or country's legal age of majority if \\>18 years), at the time of signing the informed consent.\n\nCancer diagnosis:\n\n* Histologically or cytologically confirmed diagnosis of advanced unresectable or metastatic GC or Siewert Type 2 \\& 3 GEJ.\n* Participants with unknown HER2\u002Fneu status must have their HER2\u002Fneu status determined locally. Participants with HER2\u002Fneu negative are eligible. Participants with HER2\u002Fneu positive tumors must have documentation of disease progression on treatment containing an approved HER2 targeted therapy to be eligible.\n\nPrior anticancer therapy:\n\n\\- Participants should have failed or relapsed after at least 1 prior line of treatment which may or may not include an anti-PD1\u002FPD-L1-based treatment or anti-Claudin 18.2 based treatment depending on local standard of care.\n\nMeasurable Disease:\n\n\\- At least 1 measurable lesion per RECIST 1.1 criteria.\n\nExclusion Criteria:\n\nMedical conditions\n\n* Eastern Cooperative Oncology Group(ECOG)performance status of ≥2.\n* Predicted life expectancy ≤3 months.\n* Diagnosed of any other malignancies, either progressing or requiring active treatments, within 2 years prior to enrollment.\n* Active brain metastases or leptomeningeal metastases.\n* Known microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) tumor.\n* History of treatment-related immune-mediated (or immune-related) AEs from immune- modulatory agents (including but not limited to anti-PD1\u002FPD-L1 agents and anti cytotoxic T lymphocyte associated protein 4 monoclonal antibodies) that caused permanent discontinuation of the agent, or that were Grade 4 in severity, or have not resolved to Grade ≤1.\n* Has any condition requiring ongoing\u002Fcontinuous corticosteroid therapy (\\>10 mg prednisone\u002Fday or an anti-inflammatory equivalent) within 1 week prior to the first dose of the study medicine.\n* Any clinically significant cardiac (including valvular) or vascular (thromboembolic disorders) disease, within 6 months prior to the first IMP administration.\n* Ongoing or recent (within 2 years) evidence of significant autoimmune disease that required treatment with systemic immunosuppressive treatments, which may suggest risk for immune-related AEs (irAEs).\n* Has a known history or any evidence of interstitial lung disease or active, non-infectious pneumonitis within 3 years prior to the first dose of the study drug.\n* Organ transplant requiring immunosuppressive treatment.\n* Uncontrolled or active infection with human immunodeficiency virus (HIV ), hepatitis B, or hepatitis C infection, or has a diagnosis of immunodeficiency.\n\nNote: Other Inclusion\u002FExclusion criteria may apply. The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.","ALL","18 Years",{"count":19,"type":20},30,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","This is a Phase 2, open-label, dose optimization\u002Fexpansion study to assess the preliminary efficacy and safety of SAR445877 as a monotherapy for Chinese participants aged at least 18 years with advanced Gastric Cancer(GC)\u002FGastroesophageal Junction cancer (GEJ). Participants with advanced GC\u002FGEJ who relapsed to at least 1 prior regimen which may or may not include an anti-PD1\u002FPD-L1-based treatment depending on local standard of care, regardless combined positivity score (CPS) will be randomized in this study.\n\nIn this study, SAR445877 will be assessed as a monotherapy in approximately 30 participants with advanced unresectable or metastatic GC or Siewert Type 2 and 3 GEJ, and for whom receiving the standard of care (SOC) is not in his or her best interest, or where no SOC is established. Human epidermal growth factor receptor 2 (HER2) positive cases will not be eligible unless they have progressed on a HER2 targeted therapy. Those participants should have received at least 1 prior line of anti-cancer treatment which may or may not include an anti-PD1\u002FPD-L1-based treatment depending on local standard of care. Metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) cases are not eligible.",[26,27],"Gastric Cancer","Oesophageal Carcinoma","RECRUITING","2026-07-16",{"date":31,"type":32},"2026-07-20","ACTUAL",{"date":34,"type":32},"2026-07-01",{"date":36,"type":20},"2028-08-02",{"name":38,"class":39},"Sanofi","INDUSTRY",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":49,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":53,"conditions":54,"keywords":64,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":40},"100621015","mrinrt-swansea-university-and-swwcc-collaboration-study-100621015","NCT07365124","MRinRT: Swansea University and SWWCC Collaboration Study.","Developing and Optimising the Use of Magnetic Resonance Imaging and Spectroscopy in Radiotherapy (MRinRT) Pathways: Investigating Avenues to Improve Outcomes for Patients and the Assessment of Treatment Response.","MRinRT","Inclusion Criteria for health volunteers:\n\n* Free from medical conditions that could confound imaging or study results\n* Eligible for MRI\n\nInclusion Criteria for patients:\n\n* Confirmed diagnosis of invasive carcinoma at the relevant tumour\u002Ftarget sites listed in this protocol\n* Scheduled to receive radiotherapy to the target site\n* ECOG performance status of 0-2\n* Eligible for MRI (determined through MRI safety screening)\n\nExclusion Criteria:\n\n* Presence of medical conditions that may interfere with study outcomes or data interpretation\n* Use of regular medications that could affect imaging results or safety\n* Any contraindications to MRI scanning, including but not limited to claustrophobia, reduced thermal regulatory capabilities, MR Unsafe implants and foreign bodies.",true,{"count":51,"type":20},165,"OBSERVATIONAL","The aim of this study is to learn whether using MRI (magnetic resonance imaging) scans to plan radiotherapy is better than using CT (computed tomography) scans alone. The main questions it aims to answer is:\n\n* Can MRI scan images be adjusted to make the tumour and normal tissues easier to see?\n* Does adding MRI to a radiotherapy planning CT make the radiotherapy plan more precise?\n* Can MRI be used to adjust a radiotherapy plan during a course of treatment to make it more precise, and might that reduce the side effects?\n* Are there particular MRI scans that can predict how a tumour will respond to radiotherapy or how likely the patient is to have side effects?\n\nThis study will assess current MRI scanning procedures and ensure these are adjusted to best suit radiotherapy planning. It will also provide pilot data evaluating:\n\n1. MRI-adapted radiotherapy Usually, radiotherapy plans are based on a pre-treatment planning CT scan. Unless an issue is detected the patient would complete their whole course of radiotherapy on this plan. This does not account for changes in position\u002Fsize\u002Fshape of the tumour that occur over the whole treatment course. Clinicians therefore increase the size of the tumour\u002Ftarget to account for these uncertainties, which can increase side effects. This study will assess the potential to reduce side effects from radiotherapy by using repeat MRI scans and replanning during the treatment course (MRI-adaptive radiotherapy).\n2. Imaging biomarkers MRI sequences can be used to predict response to radiotherapy or chance of developing side effects. This study will identify potential MRI sequences that may be used as imaging biomarkers, to guide the development of future clinical trials.\n\nThe study will be undertaken at SBUHB, lasting 4 years, and involving ≤15 healthy volunteers and ≤150 patients.",[55,56,57,58,59,60,61,27,62,26,63],"Carcinoma","Glioblastoma","Radiotherapy","MRI","MRI-guided Adaptive Radiotherapy","MRI Scanner Configuration","MRI Image Enhancement","Pancreas Carcinoma","Brain (Nervous System) Cancers",[58,57,65,66],"MRI adaptive radiotherapy","MRI Imaging Biomarker","NOT_YET_RECRUITING","2026-04-29",{"date":70,"type":32},"2026-04-30",{"date":72,"type":20},"2026-05",{"date":74,"type":20},"2032-01",{"name":76,"class":77},"Swansea Bay University Health Board","OTHER"]